Nektar Gets $50M Deal From Amgen

Xconomy San Francisco — 

Nektar Therapeutics (NASDAQ: NKTR), the San Carlos, CA-based biotech company, has struck a $50 million agreement to manufacture certain polymers for Amgen, according to a Reuters report. The polymers are a key ingredient in pegfilgrastim (Neulasta) a drug used to stimulate production of infection-fighting white blood cells in cancer patients suffering from the side effects of chemotherapy.